You are here

Oncologie

Lopende studies

Borst

A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator’s Choice Chemotherapy in HER2-low, Hormone Receptor Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06)

Hoofd en nek

Phase 3 Randomized, Double-blind, Multicenter, Global Study of Monalizumab or Placebo in Combination With Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With an Immune Checkpoint Inhibitor (Interlink-1)

Melanoom

Blood groups as biomarker to optimize odds of response to anti-PD-1 drugs (blood trial). An investigator-initiated, multicenter, prospective biomarker study in patients with advanced melanoma treated with anti-PD-1 monotherapy (prescribed within its approved indication as per usual practice) in the first-line setting (Blood trial)

Nier

Real patient life treatment with cabozantinib in patients with advanced or metastatic RCC: a descriptive and prospective non-interventional study (Replica)

Studies voor de toekomst

Borst

A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib plus Standard Adjuvant Endocrine Therapy in Participants with High-Risk, Node-Positive, HR+, HER-2+ Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy (I3Y-MC-JPCW)

Prostaat

A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with Metastatic Castration-Resistant Prostate Cancer (Contact-02)

Urotheelcel/blaas

An open-label, randomized, controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab with or without chemotherapy, versus chemotherapy alone in previously untreated locally advanced or metastatic urothelial cancer (SGN22E-003)

A phase III, randomized, open label, multi-center, global study to determine the efficacy and safety of Durvalumab in combination with Gemcitabine+ Cisplatin for neoadjuvant treatment followed by Durvalumab alone for adjuvant treatmentin patients with muscle-invasive bladder cancer. Patients randomized to the 2 treatment arms, arm 1 or arm 2 , will be treated according to their renal function. (Niagara)

 

Contact studieteam
e  ctc.onco@azdelta.be
Rina Talpe t  051 23 75 11
Els Verbruggen t 051 23 39 04
Nathalie Van Damme t 051 23 73 25